MedTrace Logo

Neoadjuvant Chemotherapy Followed by Preoperative Chemoradiation in Resectable Squamous-cell Esophageal Cancer

NCT03579004 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2018-07-06

No results posted yet for this study

Summary

This study is conducted to evaluate efficacy and safety of neoadjuvant chemotherapy followed by preoperative chemoradiotherapy in patients with resectable esophageal squamous cell carcinoma

Conditions

Interventions

DRUG

Paclitaxel

Paclitaxel is used in two cycles of neoadjuvant chemotherapy and concomitant chemoradiotherapy

DRUG

Cisplatin

Cisplatin is used in two cycles of neoadjuvant chemotherapy and concomitant chemoradiotherapy

DRUG

Fluorouracil

Fluorouracil is used in two cycles of neoadjuvant chemotherapy

RADIATION

chemoradiotherapy

Distant 3D radiotherapy, single dose 2 Gray (Gy), total dose 44Gy.

PROCEDURE

Ivor Lewis esophagogastrectomy

Open Ivor Lewis esophagogastrectomy

Sponsors & Collaborators

  • Mona Frolova

    lead OTHER

Principal Investigators

  • Alexey Tryakin, MD, PhD · N.N.Blokhin Russian Cancer Research Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-10
Primary Completion
2020-07-10
Completion
2020-07-10

Countries

  • Russia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03579004 on ClinicalTrials.gov